{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:31:02Z","timestamp":1786336262298,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>This case report describes a patient with metastatic hormone-sensitive prostate cancer (mHSPC), high tumor burden, and concurrent HIV infection receiving continuous efavirenz (a potent CYP3A4 inducer), who was treated with an intensified regimen based on androgen deprivation therapy (ADT) combined with the novel androgen receptor inhibitor rezvilutamide. Under rigorous multidisciplinary monitoring, this regimen achieved a rapid and profound response, characterized by a decline in prostate-specific antigen (PSA) levels from 21,788.320 ng\/mL to 4.315 ng\/mL, significant clinical improvement, sustained HIV viral suppression, and a favorable short-term tolerability profile. This case directly addresses the controversies and challenges regarding the use of intensified therapy in patients with comorbidities in current clinical practice, suggesting that key drug-drug interaction barriers may be manageable through personalized strategies and proactive management. This case provides a practical reference for implementing guideline-recommended treatment intensification principles in similar complex clinical scenarios, offering clinically relevant insights.<\/jats:p>","DOI":"10.3389\/fonc.2026.1864715","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:43Z","timestamp":1786335763000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rezvilutamide combined with ADT in an HIV-positive patient with high-volume mHSPC on efavirenz-based antiretroviral therapy: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Heng","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tailin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yundie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Ya\u2019an People\u2019s Hospital","place":["Ya\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6973","article-title":"Comparison of systemic treatments for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr076","article-title":"Cancer burden in the HIV-infected population in the United States","volume":"103","author":"Shiels","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.61","article-title":"Management of prostate cancer in HIV-positive patients","volume":"7","author":"Wosnitzer","year":"2010","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00586-7","article-title":"Clinical management and outcomes of HIV-positive patients newly diagnosed with prostate cancer: a single institution experience","volume":"27","author":"Markowski","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.276","article-title":"Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics","volume":"91","author":"Kharasch","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000003269","article-title":"Effects of the androgen receptor inhibitor enzalutamide on the pharmacokinetics of dolutegravir and tenofovir: a case report","volume":"36","author":"Londero","year":"2022","journal-title":"Aids"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpha.2025.101232","article-title":"Novel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance","volume":"15","author":"Wang","year":"2025","journal-title":"J Pharm Anal"},{"key":"B8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/mdb2.70020","article-title":"Towards comprehensive chronic disease control: prevention, early detection, and integrated management","volume":"2","author":"Sun","year":"2026","journal-title":"Med Bull"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00507-1","article-title":"Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial","volume":"23","author":"Gu","year":"2022","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.22541\/au.167117778.83793750\/v1","article-title":"Evaluation of the pharmacokinetic interactions of rezvilutamide (SHR3680) with midazolam, S-warfarin and omeprazole in patients with prostate cancer","author":"Zhu","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15528","article-title":"A single-centre, open-label, single-arm, fixed-sequence pharmacokinetic study of SHR3680 on repaglinide and bupropion in prostate cancer patients","volume":"89","author":"Dai","year":"2023","journal-title":"Br J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410x.2008.07474.x","article-title":"Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study","volume":"101","author":"Pantanowitz","year":"2008","journal-title":"BJU Int"},{"key":"B14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/bju.13097","article-title":"Clinicopathological characteristics and management of prostate cancer in the human immunodeficiency virus (HIV)-positive population: experience in an Australian major HIV centre","volume":"116","author":"Ong","year":"2015","journal-title":"BJU Int"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.06.008","article-title":"Evaluating treatment efficacy in metastatic hormone-sensitive prostate cancer patients with visceral disease: a systematic review and network meta-analysis","volume":"9","author":"Flauto","year":"2026","journal-title":"Eur Urol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/mdb2.70004","article-title":"The longer, the better? The past, present and the future of long cell\u2010free DNA\u2010based liquid biopsy","volume":"1","author":"Choy","year":"2025","journal-title":"Med Bull"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864715\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T04:22:44Z","timestamp":1786335764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1864715\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":16,"alternative-id":["10.3389\/fonc.2026.1864715"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1864715","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1864715"}}